Analysis and Commentary STEVEN GROSSMAN 9/24/21 Analysis and Commentary STEVEN GROSSMAN 9/24/21 Consequences of an FDA shutdown at the beginning of FY 22 Read More Advocacy at a Glance STEVEN GROSSMAN 9/24/21 Advocacy at a Glance STEVEN GROSSMAN 9/24/21 Shutdown possible; Updates on food safety and OTC monographs Read More Analysis and Commentary STEVEN GROSSMAN 9/17/21 Analysis and Commentary STEVEN GROSSMAN 9/17/21 Q&A on what happens if a CR isn’t passed; FDA’s role is ARPA-H is created Read More Advocacy at a Glance STEVEN GROSSMAN 9/17/21 Advocacy at a Glance STEVEN GROSSMAN 9/17/21 FY 22 Continuing Resolution (CR) up next; best scenario for FDA; FDA aided by Reconciliation if it passes Read More Analysis and Commentary STEVEN GROSSMAN 9/10/21 Analysis and Commentary STEVEN GROSSMAN 9/10/21 Clarifying some issues about FDA budget and appropriations. Read More Advocacy at a Glance STEVEN GROSSMAN 9/10/21 Advocacy at a Glance STEVEN GROSSMAN 9/10/21 Potential for a long endgame on appropriations; A government shutdown is highly unlikely, but not unimaginable. Read More Analysis and Commentary STEVEN GROSSMAN 9/3/21 Analysis and Commentary STEVEN GROSSMAN 9/3/21 The difference between micro- and macro-budgetary issues and how they affect FDA Read More Advocacy at a Glance STEVEN GROSSMAN 9/3/21 Advocacy at a Glance STEVEN GROSSMAN 9/3/21 House/Senate Appropriations have finished Ag/FDA funding, long end game lies ahead; FDA Rulemaking Authority restored, Sunset Rule delayed Read More
Analysis and Commentary STEVEN GROSSMAN 9/24/21 Analysis and Commentary STEVEN GROSSMAN 9/24/21 Consequences of an FDA shutdown at the beginning of FY 22 Read More
Advocacy at a Glance STEVEN GROSSMAN 9/24/21 Advocacy at a Glance STEVEN GROSSMAN 9/24/21 Shutdown possible; Updates on food safety and OTC monographs Read More
Analysis and Commentary STEVEN GROSSMAN 9/17/21 Analysis and Commentary STEVEN GROSSMAN 9/17/21 Q&A on what happens if a CR isn’t passed; FDA’s role is ARPA-H is created Read More
Advocacy at a Glance STEVEN GROSSMAN 9/17/21 Advocacy at a Glance STEVEN GROSSMAN 9/17/21 FY 22 Continuing Resolution (CR) up next; best scenario for FDA; FDA aided by Reconciliation if it passes Read More
Analysis and Commentary STEVEN GROSSMAN 9/10/21 Analysis and Commentary STEVEN GROSSMAN 9/10/21 Clarifying some issues about FDA budget and appropriations. Read More
Advocacy at a Glance STEVEN GROSSMAN 9/10/21 Advocacy at a Glance STEVEN GROSSMAN 9/10/21 Potential for a long endgame on appropriations; A government shutdown is highly unlikely, but not unimaginable. Read More
Analysis and Commentary STEVEN GROSSMAN 9/3/21 Analysis and Commentary STEVEN GROSSMAN 9/3/21 The difference between micro- and macro-budgetary issues and how they affect FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 9/3/21 Advocacy at a Glance STEVEN GROSSMAN 9/3/21 House/Senate Appropriations have finished Ag/FDA funding, long end game lies ahead; FDA Rulemaking Authority restored, Sunset Rule delayed Read More
